This map shows the geographic impact of Macdonald Js's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Macdonald Js with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Macdonald Js more than expected).
This network shows the impact of papers produced by Macdonald Js. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Macdonald Js. The network helps show where Macdonald Js may publish in the future.
Co-authorship network of co-authors of Macdonald Js
This figure shows the co-authorship network connecting the top 25 collaborators of Macdonald Js.
A scholar is included among the top collaborators of Macdonald Js based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Macdonald Js. Macdonald Js is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Js, Macdonald, et al.. (1996). Chemotherapy of adenocarcinoma of the pancreas.. PubMed. 23(2). 220–8.78 indexed citations
6.
Marciniak, E, et al.. (1996). Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study.. PubMed. 17(6). 917–22.25 indexed citations
7.
Js, Macdonald, et al.. (1993). Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.. PubMed. 12(4). 337–45.8 indexed citations
8.
Js, Macdonald, et al.. (1993). Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer.. PubMed. 11(4). 337–9.17 indexed citations
9.
Js, Macdonald, et al.. (1991). Adjuvant therapy in colorectal carcinoma.. PubMed. 18(6). 560–70.8 indexed citations
Js, Macdonald. (1987). New approaches to management of colorectal carcinoma.. PubMed. 22(5). 185–90, 192, 197.4 indexed citations
12.
Js, Macdonald, et al.. (1985). Palliative chemotherapy and hormonal therapy.. PubMed. 12(4). 384–9.5 indexed citations
13.
Js, Macdonald, et al.. (1982). An introduction to current controversies in cancer management: stage I testicular cancer-a case in point.. PubMed. 66(1). 1–3.1 indexed citations
14.
Js, Macdonald, et al.. (1981). CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine) for epidermoid and large cell anaplastic carcinoma of the lung.. PubMed. 65(3-4). 317–20.4 indexed citations
15.
Bruno, Silvia, et al.. (1981). ICRF-187 in clinical oncology.. PubMed. 4(2). 143–6.5 indexed citations
16.
Js, Macdonald, et al.. (1978). Phase II trial of 5-fluorouracil, adriamycin, and mitomycin C in advanced colorectal cancer.. PubMed. 62(4). 563–5.7 indexed citations
17.
Jacobson, RJ, et al.. (1978). Probable clonal origin of acute myeloblastic leukemia following radiation and chemotherapy of colon cancer.. PubMed. 52(4). 659–63.51 indexed citations
18.
Js, Macdonald. (1978). Diagnosis and treatment of colorectal cancer.. PubMed. 106(3). 105–10.5 indexed citations
19.
Js, Macdonald, et al.. (1976). 5-Fluorouracil (5-FU), methyl-CCNU, and vincristine in the treatment of advanced colorectal cancer: phase II study utilizing weekly 5-FU.. PubMed. 60(11). 1597–600.29 indexed citations
20.
Js, Macdonald, et al.. (1976). Chemotherapy of colorectal carcinoma.. PubMed. 3(4). 415–20.11 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.